Onesource Specialty Pharma Limited has informed the Exchange about Transcript
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
OneSource Specialty Pharma posted strong FY25 results with full-year revenue of INR14,449 million (up 30% YoY) and EBITDA of INR4,665 million (more than double FY24). Q4 revenue was INR4,260 million (up 22% YoY) with operating EBITDA of INR1,825 million (up 79% YoY) at a 43% margin, and adjusted full-year PAT of INR936 million. Management reaffirmed FY28 guidance of $400 million revenue, 38-40% steady-state EBITDA margin, and 30% revenue CAGR for FY25-28. FY26 was flagged as a transition year with a tepid H1 and a stronger H2, as commercial Semaglutide supplies are expected to start from Q4 FY26 once patents expire in Canada (January 2026) and other major markets (March 2026). The order book is strong with 70+ customers, 50+ drug-device combination projects, and take-or-pay/reservation-fee arrangements with multiple partners.
Solid FY25 print and reiterated FY28 targets support the long-term growth narrative, but lumpy FY26 commercial ramp tied to customer approvals and Semaglutide launches may create near-term volatility. Capacity expansion to ~90 million units by December and debt reduction toward net debt-free status in 2-3 years are key positives for the balance sheet.